drugset
drugset / Trial / NCT00061243

Safety of and Immune Response to Polyvalent HIV-1 Vaccine in HIV Uninfected Adults

NCT00061243 ↗

Phase 1 Unknown 36 enrolled National Institute of Allergy and Infectious Diseases (NIAID)
RandomizedParallel-groupOpen-labelPrevention

Summary

This study will evaluate the safety of and immune response to a new HIV vaccine. The vaccine in this trial uses pieces of HIV DNA and HIV proteins. The vaccine itself cannot cause HIV infection or AIDS.

Timeline

Start
2004-04
Primary completion
2005-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject HIV-1 DNA vaccine Vaccine — Intramuscular
Subject protein vaccine boost Vaccine — Intramuscular

Indications

HIV infectious disease